Hospitals

Featured Clinical Trial

2:13

Cancer in your esophagus, the tube that runs from your throat to your stomach, is one of the most frequently reported and a leading cause of cancer deaths around the world. Most cases are reported in developing countries. Early esophageal cancer typically causes no symptoms. However, its chemical markers are present in the earliest stage. A new device being tested in England takes advantage of that to allow early detection of esophageal and other types of cancer. Faith Lapidus reports.
Originally published at - https://www.voanews.com/a/british-clinical-trial-begins-on-breathalyzer-...

Survivor Stories

30 Radiation, 4 Chemo Treatments, 4 Surgeries. She is a cancer survivor, a photographer, cinematographer, speaker, educator, owner and CEO of Unashamed Imaging.

Meet and greet in honor of Clare Minnerath, cancer survivor. All proceeds went to the Gloria Gemma Foundation.

Blood

Featured Hospital

2:07

The fight against childhood cancer got a big bump at Helen DeVos Children's Hospital, which welcomed a check for $1 million Monday. (Jan. 14, 2019)

Featured Articles

Metastatic melanoma has historically been very difficult to treat.  Although patients with early stage melanoma have a good survival rate, the prognosis is far worse if the cancer has spread to remote areas of the body.  With the advent of new immunological therapies such as ipilimumab (marketed as Yervoy), the odds for metastatic melanoma seem poised to improve.

The immune system leads the body's fight against infection, attacking cells that are identified as foreign.  Cancer cells are often seen as foreign by the body, and so they can also be targets of the immune system.  Immunological therapy works by enhancing this ability to recognize and remove cancer cells.  High-dose interleukin-2 (IL-2) is one of the early immunological treatments.  Although it has a modest success rate, IL-2 also has severe side effects.  

Ipilimumab is the new immunological drug on the block, appearing after decades of minimal progress.  It is a monoclonal antibody that helps to increase the body's T cell population by blocking T cell inhibitors.  Drugs of this class are called immune

Clinical trials offer treatment options that are not otherwise available to cancer patients.  Investigational cancer drugs and drug combinations may represent the best hope for certain patients, but they can only be given in the context of a clinical study.

Although many patients could personally benefit from cancer trials, many do not enroll.  According to a 2010 National Institute of Health workshop on U.S. clinical research, only 3% of adult cancer patients enter trials.  In a recent review of over 500 National Cancer Institute trials, almost 40% were unable to enroll a sufficient number of patients.  This lack of participation is more than just a problem for medical research.  It is a problem for individual patients.  For some patients, the new therapy may be their best chance.  Lack of awareness and common misconceptions, however, are often a barrier.

One of the most misunderstood aspects of trials is the use of placebos.  Cancer patients shy away because they are afraid of receiving a placebo instead of therapy.  It cannot be overemphasized; this will not happen in a

Featured Oncologist

Published on Aug 31, 2016

Phillip Martin Pierorazio, M.D. is an expert in treating urinary-tract malignancies—including kidney, bladder, prostate, testis, adrenal, penile and urethral cancers. He performs both open and minimally invasive surgeries. These include laparoscopic and robotic surgeries of the kidney, bladder, prostate, and retroperitoneal lymph node dissection for testicular cancer. He has a special interest in kidney cancer and performs such specialized procedures as partial nephrectomy for early-stage disease and high-risk surgeries for advanced urological cancers. He is the Director of the Division of Testicular Cancer and works with a number of testicular cancer advocacy groups around the country. Learn more about Dr. Pierorazio at: http://www.

Featured Products

The cover of the book "Nowhere Hair" shows a mom, little girl and dog playing on the beach. But there's something a little different about this mom: she doesn't have hair. This is the premise of "Nowhere Hair," a book written by Sue Glader to help parents explain cancer and chemotherapy treatments to children.

The book's narrator is a little girl whose mom is missing her hair. The little girl goes looking for her mother's hair all throughout her home. Her mother explains to her daughter that medicine made it fall out, and that it was nothing the little girl did to make that happen. Written in rhyme, the book covers many sensitive topics, such as cancer, wearing hats and scarves to cover a head and that some people look different, which is okay.

The LIVESTRONG.org organization selected the book for children ages 3 to 12 to help kids understand a parent's diagnosis. The Moonbeam Children's Book Awards also selected the book as its 2011 Gold Medal Winner in the "Health" category.

Author Sue Glader is a breast cancer survivor who lives in Marin County, California. She

http://www.NowhereHair.com. Life can change on a dime. It's what you do after you pick up the pieces that counts.

You Can Help

12:56
Team Xplore's picture
1072 views

This interview was taped in April 2013, prior to the "Fashion For Jandie" benefiting event.

Jandie's story is long and heart breaking about her battle with stage four Mesenchymal Chondrosarcoma; But to summarize it- in the beginning, she was rejected by doctors when complaining about her excruciating leg pain, being accused of only wanting pain killers. They eventually sent her to physical therapy creating pressure and strain, thus causing her leg to break, all the while not knowing she had bone cancer. Since the doctors pushed her away instead of trying to figure out the issue, her cancer then spread to her lungs until it was finally found.

On February 9th, 2015, she found out the cancer was now in her brain, as well. February 11th she had emergency brain surgery and they were only able to remove 80% of the tumor, as the remaining 20% was up against a blood vessel that affects her motor skills.

Jandie has also had tremendous stress with her finances in supporting her battle against cancer. Her medical bills are deep in collections, and every month she has